American Association of Acupuncture and Oriental Medicine

We serve to advance the profession and practice of AOM

The statements and opinions contained in the articles on the American Association of Acupuncture and Oriental Medicine's (AAAOM) Blog are solely those of the individual authors and contributors and not of the AAAOM. The appearance of advertisements in the AAAOM’s publications are not a warranty, endorsement or approval of the products or their safety. The AAAOM disclaims responsibility for any loss, injury or damage to persons or property resulting from any ideas or products referred to in any article or advertisement. Readers are advised to verify any information on which they choose to rely. 


Effects of the Ganning Formula on Liver Fibrosis in Patients with Chronic Hepatitis B

06 Sep 2016 2:38 PM | AAAOM Admin (Administrator)

EFFECTS OF THE GANNING FORMULA ON LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B.

Posted By Al Stone, Saturday, May 05, 2012

J Tradit Chin Med. 2011 Dec;31(4):282-7.

EFFECTS OF THE GANNING FORMULA ON LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B.

Deng XLiang JWu FSLi YBTang YF.

SOURCE

Ruikang Hospital of Guangxi Traditional Chinese Medical University, Nanning 530011, Guangxi, China.

ABSTRACT

OBJECTIVE:

To investigate the clinical efficacy and safety of the Ganning formula for the treatment of liver fibrosis in patients with chronic hepatitis B.

METHODS:

In a multicenter, randomized, controlled clinical trial, 150 patients with liver fibrosis secondary to hepatitis B virus (HBV) infection were randomly assigned in equal numbers to receive either the Ganning formula (a Chinese herbal decoction; active treatment group) or oral entecavir (control group) for two 3-month courses. Patients were monitored for any treatment-induced changes in liver function test parameters (ALT, AST, and GGT), liver fibrosis markers (LN, HA, IV-C, and PCIII), HBV DNA level, hepatosplenic imaging, quality of life scores, or psychological and social functioning scores. Patients were also observed for any adverse effects.

RESULTS:

After treatment, patients in both groups experienced significant improvements in liver function, HBV DNA load, hepatosplenic B-mode ultrasonography, quality of life, and psychological and social functioning (P < 0.05 or P < 0.01). Patients receiving the Ganning formula achieved greater improvements in HA, IV-C, quality of life, and psychological and social functioning compared with those on entecavir (P < 0.05 or P < 0.01). There were no abnormal changes in blood tests, urine, feces, renal function, or electrocardiogram. Additionally, no adverse effects were observed in any patients in either group.

CONCLUSIONS:

The Ganning formula appears to have the potential to inhibit liver fibrosis and therefore improve liver function by inhibiting HBV replication in patients with chronic hepatitis B. Additionally, this formula is helpful in improving quality of life and psychological and social functioning. 

PMID: 22462232 [PubMed - indexed for MEDLINE]

Tags:  Baraclude  entecavir  hepatitis B  liver fibrosis  research



PO Box 96503 #44114, Washington DC 20090-6503

Reach us at admin@aaaomonline.org

Powered by Wild Apricot Membership Software